Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
9.35
+0.03 (0.27%)
At close: Sep 25, 2026, 4:00 PM EDT
9.44
+0.09 (1.02%)
After-hours: Sep 25, 2026, 7:30 PM EDT
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
100
Market Cap
127.51M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| LENZ Therapeutics | 21.48M |
| Caribou Biosciences | 10.04M |
| NRx Pharmaceuticals | 3.39M |
| Kazia Therapeutics | 1.27M |
| MediciNova | 920.48K |
| Inovio Pharmaceuticals | 65.34K |
IMUX News
- 17 days ago - Immunic Transcript: R&D Day 2026 - Transcripts
- 17 days ago - Immunic Slides: FY 2026 - Filings
- 23 days ago - Immunic Slides: Corporate presentation - Filings
- 24 days ago - Immunic Slides: Investor presentation - Filings
- 25 days ago - Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 - PRNewsWire
- 26 days ago - Immunic price target raised to $29 from $19 at Roth Capital - TheFly
- 26 days ago - Immunic appoints Chitrang Dave as chief data, digital officer - TheFly
- 26 days ago - Immunic Appoints Chitrang Davé as Chief Data and Digital Officer - PRNewsWire